keyword
MENU ▼
Read by QxMD icon Read
search

Psychosis alzheimer

keyword
https://www.readbyqxmd.com/read/29764230/the-modern-role-of-antipsychotics-for-the-treatment-of-agitation-and-psychosis-in-alzheimer-s-disease
#1
Byron Creese, Miguel Vanconcelos Da Silva, Iskandar Johar, Clive Ballard
Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, stroke, accelerated cognitive decline and mortality). Areas covered: This review outlines the current guidance on antipsychotic usage and the evidence of their continued usage against a backdrop of emerging pharmacological treatments and an increasing emphasis on the importance of non-pharmacological interventions...
May 15, 2018: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/29602454/optimise-the-microbial-flora-with-milk-and-yoghurt-to-prevent-disease
#2
James A Morris
Pathogenic bacteria, which are temporary or permanent members of our microbial flora, cause or contribute to a wide range of human disease at all ages. Conditions include Alzheimer's disease, atherosclerosis, diabetes mellitus, obesity, cancer, autoimmunity and psychosis, amongst others. The mechanism of damage is inflammation which can be chronic or acute. An optimal microbial flora includes a wide range of pathogenic bacteria in low dose. This allows specific immunity to be developed and maintained with minimal inflammatory damage...
May 2018: Medical Hypotheses
https://www.readbyqxmd.com/read/29564993/risk-of-dementia-associated-with-psychotic-disorders-in-later-life-the-health-in-men-study-hims
#3
Osvaldo P Almeida, Andrew H Ford, Graeme J Hankey, Bu B Yeap, Jonathan Golledge, Leon Flicker
BACKGROUND: Recent research has identified several potentially modifiable risk factors for dementia, including mental disorders. Psychotic disorders, such as schizophrenia and delusional disorder, have also been associated with increased risk of cognitive impairment and dementia, but currently available data difficult to generalise because of bias and confounding. We designed the present study to investigate if the presence of a psychotic disorder increased the risk of incident dementia in later life...
March 22, 2018: Psychological Medicine
https://www.readbyqxmd.com/read/29558759/vitamin-b12-in-association-with-antipsychotic-drugs-can-modulate-the-expression-of-pro-anti-inflammatory-cytokines-in-alzheimer-disease-patients
#4
Alireza Vakilian, Seyed Moein Razavi-Nasab, Ali Ravari, Tayebeh Mirzaei, Amir Moghadam-Ahmadi, Nazanin Jalali, Reza Bahramabadi, Mohammadtaghi Rezayati, Amin Yazdanpanah-Ravari, Farhad Bahmaniar, Mohammad Reza Bagheri, Mahmood Sheikh Fathollahi, Gholamreza Asadikaram, Mohammad Kazemi Arababadi
INTRODUCTION: Patients with Alzheimer disease (AD) suffer from psychotic symptoms including pain. The current antipsychotic drugs confer limited effectiveness, and hence new strategies are being designed to decrease pain in order to increase antipsychological effectiveness. Vitamin B12 is a safe supplementary drug to decrease pain. Additionally, cytokines participate in the pathogenesis of immune-related diseases such as AD. Thus, the main aim of this clinical trial study was to determine the effects of treatment with risperidone and quetiapine, as antipsychotic drugs, with and without vitamin B12 on the psychotic symptoms of AD patients and the expression of IL-6, IL-8, tumor growth factor (TGF)-β, tumor necrosis factor (TNF)-α, and endothelin (ET)-1)...
March 20, 2018: Neuroimmunomodulation
https://www.readbyqxmd.com/read/29553944/psychosis-in-cognitively-asymptomatic-elderly-subjects-is-associated-with-neuritic-plaque-load-not-neurofibrillary-tangles
#5
Julia Kim, Tom A Schweizer, Corinne E Fischer, David G Munoz
INTRODUCTION: Despite having severe Alzheimer disease pathology, some individuals remain cognitively asymptomatic (cASYM). To explore noncognitive manifestations in these cASYM individuals, we aim to investigate the prevalence and pathologic substrates of psychosis. METHODS: Data were obtained from the National Alzheimer's Coordinating Center. The Neuropsychiatric Inventory Questionnaire, quick version was used to evaluate presence of psychosis. Subjects with Mini-Mental Status Examination score of ≥24 with frequent neuritic plaques (NPs) were defined as NPcASYM, and those with Braak and Braak stage of neurofibrillary tangles of V/VI were defined as NTcASYM (both groups collectively designated cASYM)...
March 16, 2018: Alzheimer Disease and Associated Disorders
https://www.readbyqxmd.com/read/29464550/clinical-pharmacokinetics-and-pharmacodynamics-of-drugs-in-the-central-nervous-system
#6
REVIEW
Nithya Srinivas, Kaitlyn Maffuid, Angela D M Kashuba
Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with a high attrition rate in the development of CNS drugs. The failure of clinical trials for CNS therapies can be partially explained by factors related to pharmacokinetics/pharmacodynamics (PK/PD), such as lack of efficacy or improper selection of the initial dosage. A focused assessment is needed for CNS-acting drugs in first-in-human studies to identify the differences in PK/PD from animal models, as well as to choose the appropriate dose...
February 20, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29452684/evaluation-of-the-safety-tolerability-and-efficacy-of-pimavanserin-versus-placebo-in-patients-with-alzheimer-s-disease-psychosis-a-phase-2-randomised-placebo-controlled-double-blind-study
#7
Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos, Bruce Coate, James M Youakim, Randall Owen, Srdjan Stankovic
BACKGROUND: Pimavanserin is a selective 5-HT2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis. METHODS: We did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study...
March 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29452674/pimavanserin-for-patients-with-alzheimer-s-disease-psychosis
#8
Lon S Schneider
No abstract text is available yet for this article.
March 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29439333/risk-of-conversion-to-dementia-in-a-mild-behavioral-impairment-group-compared-to-a-psychiatric-group-and-to-a-mild-cognitive-impairment-group
#9
Fernando E Taragano, Ricardo F Allegri, Silvina L Heisecke, María I Martelli, Mónica L Feldman, Viviana Sánchez, Virginia A García, Graciela Tufro, Diego M Castro, Patricio Perez Leguizamón, Verónica Guelar, Eva Ruotolo, Cecilia Zegarra, Carol Dillon
BACKGROUND: There is insufficient available information on behavioral changes in the absence of cognitive impairment as factors increasing the risk of conversion to dementia. OBJECTIVE: To observe and analyze patients with mild behavioral impairment (MBI), mild cognitive impairment (MCI), and a psychiatry group (PG) to compare the risk of progression to dementia. METHODS: From 677 initially assessed ≥60-year-old patients, a series of 348 patients was studied for a five-year period until censoring or conversion to dementia: 96 with MBI, 87 with MCI, and 165 with general psychiatry disorders, including 4 subgroups: Anxiety, Depression, Psychosis and Others...
2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29432500/large-animals-as-potential-models-of-human-mental-and-behavioral-disorders
#10
REVIEW
Michał Danek, Janusz Danek, Aleksander Araszkiewicz
Many animal models in different species have been developed for mental and behavioral disorders. This review presents large animals (dog, ovine, swine, horse) as potential models of this disorders. The article was based on the researches that were published in the peer-reviewed journals. Aliterature research was carried out using the PubMed database. The above issues were discussed in the several problem groups in accordance with the WHO International Statistical Classification of Diseases and Related Health Problems 10thRevision (ICD-10), in particular regarding: organic, including symptomatic, disorders; mental disorders (Alzheimer's disease and Huntington's disease, pernicious anemia and hepatic encephalopathy, epilepsy, Parkinson's disease, Creutzfeldt-Jakob disease); behavioral disorders due to psychoactive substance use (alcoholic intoxication, abuse of morphine); schizophrenia and other schizotypal disorders (puerperal psychosis); mood (affective) disorders (depressive episode); neurotic, stress-related and somatoform disorders (posttraumatic stress disorder, obsessive-compulsive disorder); behavioral syndromes associated with physiological disturbances and physical factors (anxiety disorders, anorexia nervosa, narcolepsy); mental retardation (Cohen syndrome, Down syndrome, Hunter syndrome); behavioral and emotional disorders (attention deficit hyperactivity disorder)...
December 30, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/29380275/in-schizophrenia-depression-anxiety-and-physiosomatic-symptoms-are-strongly-related-to-psychotic-symptoms-and-excitation-impairments-in-episodic-memory-and-increased-production-of-neurotoxic-tryptophan-catabolites-a-multivariate-and-machine-learning-study
#11
Buranee Kanchanatawan, Supaksorn Thika, Sunee Sirivichayakul, André F Carvalho, Michel Geffard, Michael Maes
The depression, anxiety and physiosomatic symptoms (DAPS) of schizophrenia are associated with negative symptoms and changes in tryptophan catabolite (TRYCAT) patterning. The aim of this study is to delineate the associations between DAPS and psychosis, hostility, excitation, and mannerism (PHEM) symptoms, cognitive tests as measured using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) and IgA/IgM responses to TRYCATs. We included 40 healthy controls and 80 participants with schizophrenia...
April 2018: Neurotoxicity Research
https://www.readbyqxmd.com/read/29299155/neuroprotection-by-aripiprazole-against-%C3%AE-amyloid-induced-toxicity-by-p-ck2%C3%AE-activation-via-inhibition-of-gsk-3%C3%AE
#12
So Youn Park, Hwa Kyoung Shin, Won Suk Lee, Sun Sik Bae, Koanhoi Kim, Ki Whan Hong, Chi Dae Kim
Psychosis is reported over 30% of patients with Alzheimer's disease (AD) in clinics. Aripiprazole is an atypical antipsychotic drug with partial agonist activity at the D2 dopamine and 5-HT1A receptors with low side-effect profile. We identified aripiprazole is able to overcome the amyloid-β (Aβ)-evoked neurotoxicity and then increase the cell viability. This study elucidated the mechanism(s) by which aripiprazole ameliorates Aβ1-42-induced decreased neurite outgrowth and viability in neuronal cells. Pretreatment with aripiprazole increased Brain-derived neurotrophic factor (BDNF) mRNA and protein expressions in N2a cells...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29231139/catechol-o-methyltransferase-cognition-and-alzheimer-s-disease
#13
Matea Nikolac Perkovic, Dubravka Svob Strac, Lucija Tudor, Marcela Konjevod, Gordana Nedic Erjavec, Nela Pivac
OBJECTIVE: Cognition is a complex trait representing a set of all mental abilities and processes related to knowledge. Although diverse brain regions are involved, most cognitive processes appear to engage cortical regions. The activity of dopaminergic neurons in prefrontal cortex represents a biological substrate underlying cognitive functions. Alzheimer's disease (AD) is the most frequent dementia associated with cognitive impairments. Cognitive impairment in AD starts slow with discrete deterioration in memory, language, thinking and reasoning, but it progresses into more severe and debilitating cognitive dysfunction...
December 11, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/29174998/psychosis-and-clinical-outcomes-in-alzheimer-disease-a-longitudinal-study
#14
Michael H Connors, David Ames, Michael Woodward, Henry Brodaty
OBJECTIVE: Psychotic symptoms are a common feature in Alzheimer disease (AD), occurring in approximately 40% of patients. These symptoms are associated with worse clinical outcomes. Comparatively little research, however, has distinguished delusions and hallucinations, which may have distinct clinical, neuropathological, and genetic correlates. To address this, the current study examined the clinical outcomes associated with delusions and hallucinations in AD. DESIGN: Three-year observational study...
March 2018: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/29143483/the-impact-of-mental-health-comorbidities-on-adherence-to-buprenorphine-a-claims-based-analysis
#15
Megan Litz, Douglas Leslie
BACKGROUND AND OBJECTIVES: Previous research has been inconclusive about whether opioid-dependent patients with psychiatric comorbidities have shorter treatment retention and higher relapse rates. This study aims to evaluate the impact of mental health comorbidities on adherence to buprenorphine using a large, national health insurance claims data base. METHODS: We used MarketScan® data from 2012 to 2014 to perform this analysis. Inclusion criteria included all patients with an opioid use disorder-related ICD-9 code who had been prescribed buprenorphine (n = 2947)...
November 16, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/29107450/epilepsy-as-a-network-disorder-1-what-can-we-learn-from-other-network-disorders-such-as-autistic-spectrum-disorder-and-mood-disorders
#16
REVIEW
Andres M Kanner, Helen Scharfman, Nathalie Jette, Evdokia Anagnostou, Christophe Bernard, Carol Camfield, Peter Camfield, Karen Legg, Ilan Dinstein, Peter Giacobbe, Alon Friedman, Bernd Pohlmann-Eden
Epilepsy is a neurologic condition which often occurs with other neurologic and psychiatric disorders. The relation between epilepsy and these conditions is complex. Some population-based studies have identified a bidirectional relation, whereby not only patients with epilepsy are at increased risk of suffering from some of these neurologic and psychiatric disorders (migraine, stroke, dementia, autism, depression, anxiety disorders, Attention deficit hyperactivity disorder (ADHD), and psychosis), but also patients with these conditions are at increased risk of suffering from epilepsy...
December 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29073741/a-systematic-review-of-the-effectiveness-of-medical-cannabis-for-psychiatric-movement-and-neurodegenerative-disorders
#17
REVIEW
Keane Lim, Yuen Mei See, Jimmy Lee
The discovery of endocannabinoid's role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The present review aimed to synthesize and evaluate the available evidences on the efficacy of cannabis and its derivatives for psychiatric, neurodegenerative and movement disorders. A systematic search of randomized controlled trials of cannabis and its derivatives were conducted via databases (PubMed, Embase and the Cochrane Central Register of Controlled Trials)...
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29067350/neuropsychiatric-signs-and-symptoms-of-alzheimer-s-disease-new-treatment-paradigms
#18
REVIEW
Krista L Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, Steven E Arnold, Clive Ballard, Jiska Cohen-Mansfield, Zahinoor Ismail, Constantine Lyketsos, David S Miller, Erik Musiek, Ricardo S Osorio, Paul B Rosenberg, Andrew Satlin, David Steffens, Pierre Tariot, Lisa J Bain, Maria C Carrillo, James A Hendrix, Heidi Jurgens, Brendon Boot
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD...
September 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/29067344/determining-the-impact-of-psychosis-on-rates-of-false-positive-and-false-negative-diagnosis-in-alzheimer-s-disease
#19
Corinne E Fischer, Winnie Qian, Tom A Schweizer, Zahinoor Ismail, Eric E Smith, Colleen P Millikin, David G Munoz
INTRODUCTION: The rate of clinical misdiagnosis of Alzheimer's disease (AD) and how psychosis impacts that clinical judgment is unclear. METHODS: Using data from National Alzheimer's Coordinating Center, we compared the clinical and neuropathologic diagnosis in patients with a diagnosis of AD with autopsy and in neuropathology-confirmed AD cases ( n  = 961). We determined the rate of true positives, false positives, and false negatives in patients with and without psychosis...
September 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/28990131/diagnosis-and-management-of-cognitive-and-behavioral-changes-in-dementia-with-lewy-bodies
#20
REVIEW
Babak Tousi
Proper diagnosis of dementia with Lewy bodies (DLB) in clinical practice remains suboptimal as many cases are misdiagnosed, usually as Alzheimer disease (AD) or Parkinson's disease (PD) and, in rare cases, psychosis. Therefore, it is important for patients with dementia to be thoroughly evaluated by a specialist who is familiar with current diagnostic tests and treatment options. New diagnostic criteria from the Dementia with Lewy Bodies Consortium have been developed to increase diagnostic sensitivity for DLB (Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium; McKeith et al...
October 9, 2017: Current Treatment Options in Neurology
keyword
keyword
71288
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"